| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ac8c96626cb1f1d5cb6003c42bc420fe |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2871
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-32 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1754 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 |
| filingDate |
2012-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2cec31c88b420f2b314cc2f5576986f5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f7db7d725171628a82c2eae145a72b61
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9434bffbb69625e24248cc5447727491
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b1bb5129f812d37699110fc6456013fe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf91462f358b96753130f2ecaaa9afd3 |
| publicationDate |
2014-03-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20140030188-A |
| titleOfInvention |
Risk Assessment of Cardiovascular Events Using IGFBP Fragments |
| abstract |
The present invention involves the detection of proteolytic fragments of IGFBP-4 or IGFBP-5 (insulin-like growth factor binding protein 4 or insulin-like growth factor binding protein 5) in the blood of a patient, and the risk of future major adverse cardiovascular disease. The measurement method is disclosed. The present invention provides antibodies and immunoassays suitable for specifically measuring proteolytic fragments of IGFBPs. In the present invention, the use of IGFBP fragments as blood biomarkers for predicting the risk of major adverse cardiovascular events (MACE) is presented. |
| priorityDate |
2011-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |